| Major Depressive Disorder
Aplenzin vs Viibyrd
Side-by-side clinical, coverage, and cost comparison for major depressive disorder.Deep comparison between: Aplenzin vs Viibryd with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsViibryd has a higher rate of injection site reactions vs Aplenzin based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Viibryd but not Aplenzin, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aplenzin
Viibryd
At A Glance
Oral
Once daily
Norepinephrine-dopamine reuptake inhibitor
Oral
Daily
SSRI / 5-HT1A partial agonist
Indications
- Major Depressive Disorder
- Seasonal Affective Disorder
- Major Depressive Disorder
Dosing
Major Depressive Disorder Starting dose 174 mg once daily in the morning; after 4 days, increase to target dose of 348 mg once daily.
Seasonal Affective Disorder Starting dose 174 mg once daily; after 7 days, increase to target dose of 348 mg once daily in the morning; initiate in autumn, continue through winter, taper and discontinue in early spring.
Hepatic Impairment Moderate to severe (Child-Pugh 7-15): maximum 174 mg every other day; mild (Child-Pugh 5-6): consider reducing dose and/or frequency.
Renal Impairment Consider reducing dose and/or frequency in patients with GFR less than 90 mL/min.
Major Depressive Disorder Start at 10 mg once daily with food for 7 days, then increase to 20 mg once daily; may increase up to 40 mg once daily after a minimum of 7 days between dosage increases; target dose is 20-40 mg once daily with food.
Contraindications
- Seizure disorder
- Current or prior diagnosis of bulimia or anorexia nervosa
- Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
- Concomitant use or use within 14 days of an MAOI intended to treat psychiatric disorders
- Starting APLENZIN in a patient being treated with reversible MAOIs such as linezolid or intravenous methylene blue
- Known hypersensitivity to bupropion or any ingredient of APLENZIN
- Concomitant use or within 14 days of stopping MAOIs, including linezolid or intravenous methylene blue, due to increased risk of serotonin syndrome
Adverse Reactions
Most common (>=5%) Anorexia, dry mouth, rash, sweating, tinnitus, tremor at 300 mg/day bupropion HCl SR equivalent; insomnia, headache, nausea, dizziness, constipation, anxiety also reported.
Serious Suicidal thoughts and behaviors, seizure, hypertension, activation of mania or hypomania, psychosis and other neuropsychiatric events, angle-closure glaucoma, hypersensitivity reactions including anaphylaxis and Stevens-Johnson Syndrome.
Postmarketing Stroke, complete atrioventricular block, myocardial infarction, Brugada pattern/syndrome, angioedema, DRESS, acute generalized exanthematous pustulosis, rhabdomyolysis, hepatitis, pancreatitis, aseptic meningitis.
Most common (>=5%) Diarrhea, nausea, vomiting, insomnia
Serious Suicidal thoughts and behaviors, serotonin syndrome, increased risk of bleeding, activation of mania or hypomania, discontinuation syndrome, seizures, angle-closure glaucoma, hyponatremia, sexual dysfunction
Postmarketing Irritability, sleep paralysis, hallucinations, suicide attempt, suicidal ideation, rash, urticaria, drug eruption, acute pancreatitis, anosmia, hyposmia
Pharmacology
Bupropion is an aminoketone antidepressant whose action is presumed to be mediated by noradrenergic and/or dopaminergic mechanisms; it is a relatively weak inhibitor of neuronal norepinephrine and dopamine reuptake and does not inhibit MAO or serotonin reuptake.
Vilazodone is a selective serotonin reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist thought to enhance serotonergic activity in the CNS through selective inhibition of serotonin reuptake; its exact mechanism in treating major depressive disorder is not fully understood.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aplenzin
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (10/12) · Qty limit (9/12)
Viibryd
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (9/12) · Qty limit (1/12)
UnitedHealthcare
Aplenzin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Viibryd
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Aplenzin
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (2/3)
Viibryd
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$100/momo
Aplenzin Copay Savings Program - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Viibryd.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AplenzinView full Aplenzin profile
ViibrydView full Viibryd profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.